Neurogene NGNE
NASDAQ NGNE
$25.28 -0.72 (-2.77%)
At close: Nov 10, 2026 · 4:00 PM EST

Neurogene (NGNE) Non-Current Deferred Tax Liability (2013 - 2014)

Updated

Neurogene's Non-Current Deferred Tax Liability came in at $1.8 million for Q4 2014, unchanged from $1.8 million a year earlier.

Analysis

Neurogene (NGNE) Non-Current Deferred Tax Liability (2013 - 2014) Analysis & Trends

  • Going back by year, Non-Current Deferred Tax Liability was $1.8 million in FY2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Neurogene 700.15 Mn -397.16 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 1.80 Mn
Mar 31, 2014 1.80 Mn
Dec 31, 2013 1.80 Mn
API Access

Neurogene Non-Current Deferred Tax Liability API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deferred-tax-liability&ticker=NGNE&period=max&api_key=YOUR_API_KEY